Literature DB >> 26391431

Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH.

N Khorsand1,2, A Majeed3, R Sarode4, J Beyer-Westendorf5, S Schulman3,6, K Meijer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26391431     DOI： 10.1111/jth.13148

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  18 in total

1.  Optimal management of major bleeding on DOACs: not only reversal agents.

Authors:  Silvia Galliazzo; Alessandro Squizzato
Journal:  Intern Emerg Med       Date:  2019-01-05       Impact factor: 3.397

2.  Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.

Authors:  Melanie N Smith; Lindsay Deloney; Cassandra Carter; Kyle A Weant; Evert A Eriksson
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

3.  Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.

Authors:  Wesley Zemrak; Francis Manuel; Kathryn E Smith; Stephen Rolfe; Timothy Hayes; Robert L Trowbridge; Brian Carlone; David Seder
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

Review 4.  Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding.

Authors:  Miriam Kimpton; Deborah M Siegal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis.

Authors:  Siavash Piran; Rasha Khatib; Sam Schulman; Ammar Majeed; Anne Holbrook; Daniel M Witt; Wojtek Wiercioch; Holger J Schünemann; Robby Nieuwlaat
Journal:  Blood Adv       Date:  2019-01-22

6.  Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel.

Authors:  Christopher W Baugh; Michael Levine; David Cornutt; Jason W Wilson; Richard Kwun; Charles E Mahan; Charles V Pollack; Evie G Marcolini; Truman J Milling; W Frank Peacock; Rachel P Rosovsky; Fred Wu; Ravi Sarode; Alex C Spyropoulos; Todd C Villines; Timothy D Woods; John McManus; James Williams
Journal:  Ann Emerg Med       Date:  2019-11-13       Impact factor: 5.721

7.  Use and outcomes of prothrombin complex concentrate for factor Xa inhibitor-associated bleeding.

Authors:  Annabel K Frank; Previn Ganesan; Ashley Thompson; Margaret C Fang
Journal:  Thromb Res       Date:  2020-12-08       Impact factor: 3.944

8.  A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding.

Authors:  Tessa Jaspers; Kimberly Shudofsky; Menno V Huisman; Karina Meijer; Nakisa Khorsand
Journal:  Res Pract Thromb Haemost       Date:  2021-05-24

9.  Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage.

Authors:  Ava E Cascone; Mitchell J Daley; Neil Pan; Eimeira Padilla-Tolentino; Truman J Milling
Journal:  Pharmacotherapy       Date:  2021-05-17       Impact factor: 6.251

10.  Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.

Authors:  Pallavi Dev; Carol Abousaab; Cecilia Zhou; Ravi Sarode
Journal:  J Thromb Thrombolysis       Date:  2021-08-09       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.